我院Ⅰ类切口围术期抗菌药物预防应用干预性研究Δ  

Intervention Study on Perioperative Prophylactic Application of Antibiotics in Type Ⅰ Incision Operations in Our Hospital

作　　者：于卫江[1,2] 张文周[1,2] 张斌[1,2] 赵秀莉[1,2] 

机构地区：[1]郑州大学附属肿瘤医院 [2]河南省肿瘤医院药学部,郑州450003

出　　处：《中国药房》2014年第10期870-872,共3页China Pharmacy

基　　金：河南省医学科技攻关项目(No.200903146)

摘　　要：目的:探讨医院围术期抗菌药物合理使用方案的可行性。方法:分别抽取2012年1-5月、2013年1-5月Ⅰ类切口手术病历各1 500份作为非干预组及干预组,通过干预措施,对抗菌药物使用情况进行对照研究。结果:干预组Ⅰ类切口围术期预防使用抗菌药物比例为16.80%,显著低于非干预组35.00%(P<0.01);干预组、非干预组外科切口感染率分别为0.67%、0.73%;干预组给药时机合理率、使用疗程合理率、抗菌药物品种选择合理率、抗菌药物分级使用合理率分别为96.83%、97.22%、99.21%、99.60%,显著高于非干预组(P<0.01);干预组乳腺、甲状腺、体表肿瘤切除、经血管途径介入诊断手术预防使用抗菌药物比例为2.53%,较非干预组显著降低(P<0.01)。结论:干预措施对规范围术期抗菌药物的合理使用起到了积极的作用,具有可行性和有效性。OBJECTIVE： To evaluate the feasibility of perioperative rational application of antibiotics in our hospital. METH- ODS： 1 500 medical records were selected as non-intervention group and intervention group in Jan.--May 2012 and Jan.--May 2013, respectively. The utilization of antibiotics was compared by case control study. RESULTS： The perioperative prophylactic ap- plication of antibiotics in type ｜ incision operations was 16.80% in intervention group, which was significantly lower than 35.00% of non-intervention group （P^0.01）. The infection rate of surgical incision in intervention group and non-intervention group were 0.67% and 0.73%, respectively. In intervention species selection and antibiotics classification were 96.83% group, reasonable rate of delivery time, treatment course, antibacterial , 97.22%, 99.21% and 99.60%, which were significantly higher than those of non-intervention group （P^0.01）. In intervention group, the proportion of prophylactic application of antibiotics in breast operation, thyroid operation, body surface tumor resection, endovascular interventional diagnosis were 2.53%, which was signifi- cantly lower than that of non-intervention group （P〈0.01）. CONCLUSIONS： The intervention measures are feasible and effective for perioperative rational application of antibiotics.

关 键 词：I类切口手术 抗菌药物 围术期 干预 合理用药 

分 类 号：R95[医药卫生—药学] R969.3